Literature DB >> 4304570

Method for testing virus stocks for viral contaminants.

B Hampil, J L Melnick.   

Abstract

A practical method for testing the purity of virus stocks has been developed and applied to reference stocks of enteroviruses. The method requires the use of a reference antiserum that is substantially free from heterotypic antibody. When selected dilutions of this antiserum are reacted with high concentrations of virus, virus intentionally allowed to escape neutralization is recovered and then identified. A contaminating virus present as a minor component of the population has a far greater probability of being revealed under the conditions of this "breakthrough" test than under the commonly used virus identity tests which customarily employ approximately 100 TCD(50) of virus and, therefore, only identify the major component of the virus population. The breakthrough test described has been used for tests of 104 reference stocks of all the enteroviruses that propagate in monkey kidney cells and human amnion cells. Although all the materials had been previously tested and approved by the commonly employed virus identity test, the breakthrough test in two instances revealed contaminating heterotypic enteroviruses present at a very low titer in the stocks. Without resorting to the stringent, elaborate, and expensive tests for absolute purity, such as those that are required to assure safety of vaccines, the use of the breakthrough test described provides reasonable assurance of purity for stock viruses to be employed as diagnostic reagents or for general laboratory research purposes where a multiplicity of viral agents and antisera are required.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4304570      PMCID: PMC377604          DOI: 10.1128/am.17.1.17-20.1969

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  10 in total

1.  PRODUCTION OF HIGH-TITER ENTEROVIRUS ANTISERA IN BABOONS.

Authors:  A R OCAMPO; J L MELNICK
Journal:  Am J Hyg       Date:  1964-05

2.  TOLUCA-3, A NEWLY RECOGNIZED ENTEROVIRUS.

Authors:  L ROSEN; J KERN
Journal:  Proc Soc Exp Biol Med       Date:  1965-02

3.  PREPARATION AND STANDARDIZATION OF COXSACKIEVIRUS REFERENCE ANTISERA. I. FOR TWENTY-FOUR GROUP A VIRUSES.

Authors:  P S KAMITSUKA; T Y LOU; A FABIYI; H A WENNER
Journal:  Am J Epidemiol       Date:  1965-05       Impact factor: 4.897

4.  ON THE ALLEGED ANTIGENIC RELATION BETWEEN ECHO VIRUS TYPES 29 AND 32.

Authors:  L ROSEN; A M BEHBEHANI; P S KAMITSUKA; J KERN; E H LENNETTE; J L MELNICK; N J SCHMIDT; H A WENNER
Journal:  Proc Soc Exp Biol Med       Date:  1965-07

5.  Cationic inactivation of vacuolating virus (SV40) in poliovirus suspensions.

Authors:  C WALLIS; J L MELNICK
Journal:  Tex Rep Biol Med       Date:  1961

6.  Production and standardization of ECHO reference antisera. I. For 25 prototypic ECHO viruses.

Authors:  P S KAMITSUKA; M E SOERGEL; H A WENNER
Journal:  Am J Hyg       Date:  1961-07

7.  Virus aggregation as the cause of the non-neutralizable persistent fraction.

Authors:  C Wallis; J L Melnick
Journal:  J Virol       Date:  1967-06       Impact factor: 5.103

8.  Lack of serological relationship of ECHO virus types 1 and 12.

Authors:  M Hara; T Komatsu; M Sasaki; I Tagaya
Journal:  Proc Soc Exp Biol Med       Date:  1968-07

9.  WHO collaborative studies on enterovirus reference antisera.

Authors:  J L Melnick; B Hampil
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

10.  WHO collaborative studies on enterovirus reference antisera: second report.

Authors:  B Hampil; J L Melnick
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

  10 in total
  7 in total

1.  New human adenovirus associated with respiratory illness: candidate adenovirus type 39.

Authors:  J C Hierholzer; M C Kemp; G W Gary; H C Spencer
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

2.  Reference equine antisera to 33 human adenovirus types: homologous and heterologous titers.

Authors:  J C Hierholzer; W C Gamble; W R Dowdle
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

3.  New human adenovirus isolated from a renal transplant recipient: description and characterization of candiate adenovirus type 34.

Authors:  J C Hierholzer; N O Atuk; J M Gwaltney
Journal:  J Clin Microbiol       Date:  1975-04       Impact factor: 5.948

4.  Antigenic characterization of intermediate adenovirus 14-11 strains associated with upper respiratory illness in a military camp.

Authors:  J C Hierholzer; A Pumarola
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

5.  United Kingdom scheme for external quality assessment in virology. Part II. Specimen distribution, performance assessment, and analyses of participants' methods in detection of rubella antibody, hepatitis B markers, general virus serology, virus identification, and electron microscopy.

Authors:  S E Reed; P S Gardner; J Stanton
Journal:  J Clin Pathol       Date:  1985-05       Impact factor: 3.411

6.  Comparison of immunization methods for producing reference adenovirus antisera in horses.

Authors:  J C Hierholzer; W C Gamble; K D Quist; W A Chappell
Journal:  Appl Microbiol       Date:  1972-09

7.  New human adenovirus (candidate adenovirus type 35) causing fatal disseminated infection in a renal transplant recipient.

Authors:  H Stalder; J C Hierholzer; M N Oxman
Journal:  J Clin Microbiol       Date:  1977-09       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.